Objectives: Delirium is highly prevalent in patients with advanced cancer. This study aimed to investigate delirium rates and potential associated factors such as mortality in patients admitted to an acute palliative care unit (APCU). Our second aim was to validate the Korean version of the Memorial Delirium Assessment Scale (K-MDAS).
prevalence of delirium in an acute palliative care unit (APCU) varied by up to 42.3%, 1,2 although it is often unrecognized or under-diagnosed. 3 The occurrence of delirium leads to a poor medical outcome, including functional deficits, cognitive decline, increased length of hospitalization, and distress to patients and their caregivers. 4 Delirium has been related to increased mortality in patients receiving palliative care. 5 Some studies revealed that the higher mortality in patients with delirium receiving palliative care is also associated with cognitive impairment, age, hypoxemia, and organ failure. 6, 7 Scarpi et al (2011) proposed a palliative prognostic score to predict mortality in patients with terminal cancer based on factors such as performance score, dyspnea, and anorexia. 5 A follow-up study revealed the contribution of delirium in a prediction model of mortality. 8 Specific evidence of the factors associated with delirium and its consequences, such as mortality, would allow for better predictions of clinical outcome in patients with cancer.
The Memorial Delirium Assessment Scale (MDAS) is one of the most well-validated measures used to evaluate delirium and also
shows validity in patients with advanced cancer. 9 This scale was developed to diagnose delirium and assess symptom severity, in accordance with the diagnostic criteria of the Diagnostic and Statistical
Manual of Mental Disorders, Fourth Edition (DSM-IV). However, the optimal cutoff scores for diagnosing delirium have been reported to vary among study populations. [10] [11] [12] Although the MDAS has been translated and validated in many languages, [13] [14] [15] 
no validation study has been conducted on the Korean translation of the MDAS (K-MDAS).
Few studies have used a prospective design and specific assessment of delirium to examine the relationship between delirium and mortality after APCU discharge in advanced cancer patients. The aim of this study was to investigate the delirium rates on admission and related factors in patients with cancer who were admitted to an APCU, using validated tools to assess delirium. We also explored the predictors of 1-and 3-month mortality associated with delirium after discharge in this population. The secondary objective was to assess the validity and reliability of the K-MDAS and to determine the optimal cutoff score for diagnosing delirium in Korean patients. 19 and the DSM-IV criteria. As in a previous study, hyperactive delirium was defined by a positive score, and hypoactive delirium was defined by a negative score on the Richmond Agitation and Sedation
Scale, a subpart of the CAM. 20 Delirium severity was rated by consulting psychiatrists, who were blinded to the MDAS scores, using the Delirium Rating Scale-Revised 98 (DRS-R98 was used to compare data between the initial assessment and the follow-up assessment. The primary outcome was the delirium rate at admission and related conditions in patients admitted to the APCU.
Binary logistic regression was used to identify variables predicting delirium, and all baseline variables were included as covariates: age, sex, cancer diagnosis, educational level, marital status, smoking, BMI, ECOG PS, ESAS score, daily dose of morphine equivalents calculated from the mean daily dose of opioid, and hypnotic use. Variables with statistical significance in the univariate analysis were included in a multivariate linear regression model. We also examined factors predicting 1-and 3-month mortality using binary logistic regression.
We calculated the Cronbach's alpha coefficient and the correlation coefficient between individual items and total scores on the K-MDAS to assess the validity and reliability of the K-MDAS. Concurrent validity of the K-MDAS was evaluated using the t-test by comparing total K-MDAS scores between subjects with and without delirium. We also tested the association between K-MDAS and DRS-R98 total scores with a Pearson correlation test. Furthermore, we performed a receiver operating characteristic curve analysis to assess the accuracy and construct validity and to determine the optimal cutoff score for the K-MDAS. The optimal cutoff score was that which showed maximum sensitivity and specificity. All tests were two-tailed, and a P-value <0.05 was considered significant. All analyses were performed using SPSS for Windows software (ver. 20.0; SPSS, Inc., Chicago, USA).
Based on the previous study reporting predictors of delirium in hospitalized cancer patients 22 , we calculated the effect and sample sizes necessary to identify variables related to delirium using G*Power 3.1; with 10 predictors, the required sample size for a power of 0.80, and an alpha of 0.05 was at least 84 participants.
3 | RESULTS
| Patients in the APCU and delirium
Initially, 123 patients admitted to the APCU were deemed eligible, 21
patients were excluded due to dementia (n = 5) and refused consents (n = 16), and finally 102 patients were screened and enrolled for the baseline delirium assessment. Among them, 53 patients were re-assessed after 1 week, and 49 patients dropped out prior to the follow-up assessment due to death (n = 4), discharge (n = 43) before 1 week, and refusal to participate with no reason given (n = 2).
Of the 102 patients initially assessed, 24 (23.52%) were diagnosed with delirium, and 78 were determined to be non-delirious.
Delirious patients had significantly higher mean scores on the DRS-R98 and K-MDAS than did patients without delirium (Table 1 and supplementary Fifty-three patients were reassessed at the 1-week follow-up.
Among the 46 patients who were not delirious at the initial assessment, 13 (28.26%, conversion rate) patients developed delirium during the study period, and 20 of 53 (37.74%, occurrence rate) patients
were ultimately confirmed to be delirious. There was no case of remitted delirium during the first week. Paired t-tests revealed no significant change in total or sub scores on the DRS-R98 or K-MDAS during the week.
| Delirium and mortality
Of the 97 patients included in the mortality analysis, 88 (90.72%, 95.8% in the delirium group vs 83.3% in the non-delirium group, χ 2 = 2.422, P = 0.120) died within 3 months of enrolment. Thirty patients among 88 died within 1 month since the initial assessment; thus, the overall mortality rate at 1 month was 30.93% (45.8% for the delirium group vs 24.4% for non-delirium group, χ 2 = 4.077, P = 0.043). According to the univariate analysis, the reduced model included variables were significantly associated with mortality. As presented in Table 2 , the multivariate logistic regression analysis revealed the following variables to be significant predictors of 1-month mortality: male sex, BMI, hypnotic use, and delirium, and 3-month mortality: BMI and ECOG PS.
| Reliability and validity of the K-MDAS
The K-MDAS showed reliable internal consistency, with a Cronbach's α of 0.942. Table 3 
| DISCUSSION
In this study, the delirium rate on admission to the APCU was 23.5%, and the associated factors were older age, higher ECOG PS score, and ESAS-drowsiness. A previous study in a similar population reported a prevalence rate of delirium of 13.3% to 42.3%. 2 These varied prevalence may be due to differences in study populations, study design, and the use of validated measures for assessing delirium. 6, 23, 24 In our study, sedated patients who could not be assessed for delirium were excluded. Additionally, we included patients with advanced cancer admitted to the APCU and used both the CAM and DSM-IV diagnostic criteria to obtain more accurate delirium diagnoses by professional delirium, which may in part explain this discrepancy with regard to the associations of delirium with morphine dose. 27 Among the clinical symptoms captured by the ESAS, the severities of drowsiness, sleep disturbance, and anorexia were higher in patients with delirium than in those without. Drowsiness is related to an altered level of consciousness, the core symptom of delirium; thus, it could be perceived as a sub-threshold state for delirium. 28 Symptoms such as sleep Abbreviations: ECOG PS, Eastern Cooperative Oncology Group Performance Status Scale; ESAS, Edmonton Symptom Assessment System; DRS-R98, Delirium Rating Scale Revised-98; MDAS, Memorial Delirium Assessment Scale.
disturbance and anorexia reflect the patient's clinical status and are directly linked to the etiology of delirium. 26 Our results revealed that the 1-and 3-month mortality rates were 30.93% and 90.72%, respectively. Patients with delirium had a higher 1-month mortality rate, but there was no group difference in the 3-month mortality rates. Previous studies reported high mortality rates in patients in a palliative setting, particularly in-hospital mortality. 1, 8, 26, 29 However, we observed that most deaths occurred after discharge rather than in the hospital. These discrepancies may be attributed to differences in the populations sampled in the APCU.
We identified delirium as an independent predictor of short-term mortality in palliative care patients. The predisposing effect of delirium on mortality in the advanced care setting has been repeatedly demonstrated. 1, 8, 22, 29 The reason is not completely understood; it may be a predictor of global vulnerability of the organs and brain and may contribute to an increase in the number of complications and morbidity, which in turn lead to death. 30 Our observations suggest the importance of monitoring delirium in patients admitted to the APCU during hospitalization and at discharge. Furthermore, male gender, hypnotic use, and BMI were associated with mortality in patients with advanced cancer. Hui et al (2010) reported that male gender is a poor prognostic factor for mortality based on gender differences in comorbidities. 31 Hypnotic use in patients with cancer has been demonstrated to lead to mortality, 32 where an increased risk of falls, depression, and other adverse medical events may mediate that relationship. There are differences in the associations between BMI and mortality in patients undergoing palliative care by ethnicity, age, and disease status. 33 One study reported that a loss of skeletal muscle rather than weight and BMI was a prognostic of survival, although cancer cachexia is well known as being related to poor survival. 34 In this study, we validated the K-MDAS and determined the optimal cutoff score for a diagnosis of delirium in patients with cancer.
This study demonstrated that the K-MDAS has acceptable reliability and validity. We detected a significant difference in K-MDAS scores between patients with clinically confirmed delirium and those without delirium. This result indicated the efficacy of the K-MDAS for diagnosing and assessing the severity of delirium. A recent review on delirium measurement suggested that the DRS-R98 is one of the most useful tools to assess delirium but requires specially trained operators. 35 The MDAS was originally designed to measure delirium severity, and it also has diagnostic and screening potential. 36 The MDAS has Item-total r values were based on Spearman rank-order correlation.
Abbreviations: MDAS, Memorial Delirium Assessment Scale.
FIGURE 1
Receiver operating characteristics (ROC) analysis was performed to compare the Memorial Delirium Assessment Scale (MDAS) with the Delirium Rating Scale-Revised 98 (DRS-R98) using the Confusion Assessment Method (CAM) diagnostic criteria for delirium. The red line indicates the ROC curve of the MDAS, and the black line is that of the DRS-R98 excellent validity in the palliative care setting, although there is a lack of consensus on the optimal cutoff score for diagnosing delirium.
Breitbart (1997) originally used a cutoff score of 8 for mild delirium. 9 Several studies have investigated the diagnostic utility of the MDAS and reported different cutoff scores in different versions, such as 7 in the Spanish version, 14 7.5 in the Chinese version, 13 10 in the Japanese version, 37 and 13 in the Italian version. 38 In this study, the cutoff score of 9 yielded the highest sensitivity and specificity for diagnosing delirium in a palliative care setting. Our observations suggest that the K-MDAS is comparable to the DRS-R98 for diagnosing delirium in patients with advanced cancer. 39 
| CONCLUSION
The present study revealed the occurrence rate of delirium in hospitalized patients with advanced cancer. The prospective nature of this study, the relatively homogenous patient population, the use of specific measures of delirium supervised by trained professionals, and the inclusion of 3-month mortality data render our results helpful for assessing delirium and its consequences. Among various factors, older age, poor ECOG PS, and drowsiness were related to the presence of delirium. Similarly, specific features related to mortality, including delirium, male gender, and hypnotic use could be focused during palliative care. Our results suggest that the K-MDAS is clinically useful for screening and diagnosing delirium in the palliative care setting.
| LIMITATIONS
We could not perform a sub-analysis by motoric subtype of delirium due to the modest sample size. It is possible that we underestimated the prevalence of the hypoactive delirium type due to the exclusion of non-alert patients. As we examined the course of delirium by reassessing patients after 1 week, our observations may not fully reflect the daily fluctuating course of delirium. We performed two measurements within 24 hours and re-assessed the patient 1 week later; thus, there may have been cross contamination. In terms of the impact of delirium on mortality, especially on 3-month mortality, we could not adjust the competing risks and time-varying events.
Thus, our data should be interpreted with caution. Finally, our results cannot be generalized to other settings including hospice units.
| CLINICAL AND RESEARCH IMPLICATIONS
This study identified factors potentially related to delirium and mortality, and these clinical features should be the focus of efforts to screen for delirium in the palliative care setting. Future prospective studies including larger samples and multiple factors related to mortality in palliative care patients could be useful for identifying robust predictors of mortality, and for clarifying the underlying mechanisms. Studies focusing on hypoactive-type delirium and responses to treatment will provide more clinical information on delirium in the APCU setting.
